Weekly docetaxel in the treatment of metastatic breast cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 1047-1059

  Palmeri, Laura ^a   Vaglica, Marina ^a   Palmeri, Sergio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chemotherapy; Docetaxel; Metastatic breast cancer; Weekly

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IMATINIB; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; LACRIMATION DISORDER; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG FIBROSIS; LUNG TOXICITY; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ONYCHOLYSIS; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 56749140661     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Aihara T, Kim Y, Takatsuka Y. 2002. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol, 13:286-92.
2. Brenner H, Gondos A, Arndt V. 2007. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol, 25:3274-80.
3. Briasoulis E, Karavasilis V, Anastasopoulos D, et al. 1999. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol, 10:701-6.
4. Brugnatelli S, Danova M, De Bella MT, et al. 2002. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology, 62:33-8.
5. Burstein HJ, Harris LN, Marcom PK, et al. 2003. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol, 21:2889-95.
6. Burstein HJ, Keshaviah A, Baron AD, et al. 2007. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer, 110:965-72.
7. Burstein HJ, Manola J, Younger J, et al. 2000. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol, 18:1212-9.
8. Chan S, Friedrichs K, Noel D, et al. 1999. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol, 17:2341-54.
9. Colozza M, de Azambuja E, Personeni N, et al. 2007. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist, 12:253-70.
10. Cortes JE, Pazdur R. 1995. Docetaxel. J Clin Oncol, 13:2643-55.
11. D'Andrea GM, Seidman AD. 1997. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol, 24(Suppl 13): S13-27-S13-44.
12. D'Hondt R, Paridaens R, Wildiers H, et al. 2004. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs, 15:341-6.
13. Esteva FJ, Valero V, Booser D, et al. 2002. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol, 20:1800-8.
14. Findlay HP, Walker-Dilks C. 1998. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control, 2:140-6.
15. Ford HE, Yap YS, Miles DW, et al. 2006. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemother Pharmacol, 58:809-15.
16. Frasci G, Comella P, D'Aiuto G, et al. 2000. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol, 11:367-71.
17. Ghersi D, Wilcken N, Simes J, et al. 2005. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, (2):CD003366.
18. Ghosn M, Farhat FS, Kattan JG, et al. 2008a. Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients: A randomized multicenter phase II trial. Proc Am Soc Clin Oncol, 26:1119a.
19. Ghosn M, Kattan J, Farhat F, et al. 2008b. Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial. Cancer Chemother Pharmacol, 62:11-8.
20. Hainsworth JD, Burns HA 3rd, Erland JB, et al. 1998. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol, 16:2164-8.
21. Hainsworth JD, Burris HA 3rd, Yardley DA, et al. 2001. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol, 19:3500-5.
22. Hayat MJ, Howlader N, Reichman ME, et al. 2007. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist, 12:20-37.
23. Holmes FA, Walters RS, Theriault RL, et al. 1991. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst, 83:1797-805.
24. Hotchkiss KA, Ashton AW, Mahmood R, et al. 2002. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther, 1:1191-200.
25. Ibrahim T, Serra P, Vertogen B, et al. 2007. Doxorubicin (Dox), cyclophosphamide (Cyc) and weekly docetaxel (Doc) as first-line treatment of advanced breast cancer (ABC). Proc Am Soc Clin Oncol, 25(18S):11516a.
26. Ito Y, Aiba K, Horikoshi N, et al. 2001. Dose-finding phase I study of simultaneous weekly infusion with doxorubicin and docetaxel in patients with advanced breast cancer. Int J Clin Oncol, 6:242-7.
27. Jackisch C, Eibach H, Knuth A, et al. 2000. Phase-II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 19:417a.
28. Kornek GV, Ulrich-Pur H, Penz M, et al. 2001. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol, 19:621-7.
29. Kouroussis C, Agelaki S, Mavroudis D, et al. 2000. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 46:488-92.
30. Loeffler TM, Freund W, Droge C, et al. 1998. Activity of weekly Taxotere in patients with metastatic breast cancer [abstract]. J Clin Oncol, 17:abstr 113.
31. Luck HJ, Donnè S, Glaubitz M, et al. 1997. Phase I study of weekly docetaxel (Taxotere) in heavily pretreated breast cancer patients. Eur J Cancer, 33(s8):s158 (abstract 703).
32. Marty M, Cognetti F, Maraninchi D, et al. 2005. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 23:4265-74.
33. Meier CR, Illiger HJ, Steder M, et al. 2004. Weekly vinorelbine (VIN) vs weekly docetaxel (DOC) for metastatic breast cancer failing anthracyclines. Planned interim analysis of a randomized trial. Proc Am Soc Clin Oncol, 22(14s):774a.
34. Miles D, Chan A, Romieu G, et al. 2008. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol, 26:1011a.
35. Miller K, Wang M, Gralow J, et al. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357:2666-76.
36. Mrozek E, Ramaswamy B, Young D, et al. 2006. Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Clin Breast Cancer, 7:141-5.
37. Nabholtz JM, Gelmon K, Bontenbal M, et al. 1996. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol, 14:1858-67.
38. Nabholtz JM, Thuerlimann B, Bezwoda WR, et al. 1997. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park), 11(8 Suppl 8):25-30.
39. Nistico C, Cognetti F, Frontini L, et al. 2005. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology, 68:356-63.
40. O'Brien ME, Leonard RC, Barrett-Lee PJ, et al. 1999. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol, 10:205-10.
41. Palmeri S, Vaglica M, Spada S, et al. 2005. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study. Oncology, 68:438-45.
42. Paridaens R, Biganzoli L, Bruning P, et al. 2000. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol, 18(4):724-33.
43. Peacock NW, Infante JR, Yardley DA, et al. 2008. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 26:1032a.
44. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353:1659-72.
45. Raab G, Brugger W, Harbeck N, et al. 2002. Multi-center randomized phase II study of docetaxel (Doc) given q3w vs. q1 wk plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer (MBC). Breast Cancer Res Treat, 76 (Suppl 1):S114a.
46. Raff JP, Rajdev L, Malik U, et al. 2004. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer, 4:420-7.
47. Ramaswamy B, Elias AD, Kelbick NT, et al. 2006. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res, 12:3124-9.
48. Ramos M, Gonzalez-Ageitos A, Amenedo M, et al. 2003. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother, 15:192-7.
49. Ravdin PM, Burris HA 3rd, Cook G, et al. 1995. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol, 13:2879-85.
50. Ringel I, and Horwitz SB. 1991. Studies with RP 56976 (taxotere): a semi-synthetic analogue of taxol. J Natl Cancer Inst, 83:288-91.
51. Rivera E, Mejia JA, Arun BK, et al. 2008. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer, 112:1455-61.
52. Romond EH, Perez EA, Bryant J, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353:1673-84.
53. Rosati MS, Raimondi C, Quadrini S, et al. 2008. WALT trial (Phase I-II): Weekly non-pegylated liposomal anthracycline and taxane combination in first-line breast cancer chemotherapy. Clin Oncol, 26: 1097a.
54. Salminen E, Bergman M, Huhtala S, et al. 1999. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol, 17:1127.
55. Sedky L, Saad I, Hashem B, et al. 2002. Weekly docetaxel vs. every 3-week in advanced breast cancer: results of a pilot comparative study. Proc Am Soc Clin Oncol, 20:2013a.
56. SEER. 2008. Accessed 04 February 2008. URL: http://apps.nccd.cdc.gov/uscs/Table.aspx?Group=3f&Year= 2004&Display=n.
57. Seidman AD, Reichman BS, Crown JP, et al. 1995a. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. Clin Oncol, 13:1152-9.
58. Seidman AD, Tiersten A, Hudis C, et al. 1995b. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol, 13:2575-81.
59. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783-92.
60. Sledge GW, Neuberg D, Bernardo P, et al. 2003. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol, 21:588-92.
61. Stemmler HJ, Gutschow K, Sommer H, et al. 2001. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol, 12:1393-8.
62. Stemmler J, Mair W, Stauch M, et al. 2005. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology, 68:71-8.
63. Stockler M, Wilcken NR, Ghersi D, et al. 2000. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev, 26:151-68.
64. Tabernero J, Climent MA, Luch A, et al. 2004. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol, 15:1358-65.
65. Tedesco KL, Thor AD, Johnson DH, et al. 2004. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol, 22:1071-7.
66. Tomiak E, Piccart MJ, Kerger J, et al. 1994. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol, 12:1458-67.
67. Valero V. 1997. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol, 24(Suppl 13):S13-1-S-8.
68. Valero V, Holmes FA, Walters RS, et al. 1995. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol, 13:2886-94.
69. Waterhouse DM, Mainwaring M, Barton J, et al. 2008. Phase II pilot results of imatinib mesylate with weekly docetaxel in metastatic breast cancer. Proc Am Soc Clin Oncol, 26:1090a.
70. Wenzel C, Hussian D, Bartsch R, et al. 2004. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol, 130:400-4.
71. Wenzel C, Locker GJ, Pluschnig U, et al. 2002. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol, 50:155-9.
72. Zimatore M, Danova M, Vassallo E, et al. 2002. Weekly taxanes in metastatic breast cancer (review). Oncol Rep, 9:1047-52.